What is HC Wainwright’s Forecast for LRMR Q1 Earnings?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for Larimar Therapeutics in a report released on Tuesday, March 25th. HC Wainwright analyst E. White forecasts that the company will post earnings of ($0.43) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.54) EPS and FY2027 earnings at ($1.57) EPS.

Several other research analysts have also issued reports on the stock. Guggenheim restated a “buy” rating and issued a $26.00 price target on shares of Larimar Therapeutics in a research report on Tuesday. Truist Financial assumed coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They set a “buy” rating and a $18.00 target price for the company. Finally, Robert W. Baird dropped their price target on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday. Eleven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $20.22.

Larimar Therapeutics Stock Performance

Shares of LRMR stock opened at $2.31 on Wednesday. The business’s fifty day moving average is $3.14 and its 200-day moving average is $5.20. The stock has a market cap of $147.39 million, a PE ratio of -2.01 and a beta of 0.99. Larimar Therapeutics has a 1 year low of $2.22 and a 1 year high of $11.20.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16).

Institutional Investors Weigh In On Larimar Therapeutics

Several large investors have recently made changes to their positions in LRMR. Janus Henderson Group PLC raised its position in Larimar Therapeutics by 27.2% during the third quarter. Janus Henderson Group PLC now owns 5,566,855 shares of the company’s stock valued at $36,379,000 after acquiring an additional 1,189,467 shares in the last quarter. Blue Owl Capital Holdings LP lifted its stake in shares of Larimar Therapeutics by 11.7% in the 4th quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company’s stock valued at $18,007,000 after purchasing an additional 486,211 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in Larimar Therapeutics by 23.5% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock valued at $8,127,000 after buying an additional 399,123 shares in the last quarter. Alyeska Investment Group L.P. lifted its holdings in Larimar Therapeutics by 38.6% in the 4th quarter. Alyeska Investment Group L.P. now owns 984,077 shares of the company’s stock worth $3,808,000 after purchasing an additional 273,920 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in Larimar Therapeutics by 278.8% during the fourth quarter. Cubist Systematic Strategies LLC now owns 233,873 shares of the company’s stock worth $905,000 after purchasing an additional 172,131 shares during the period. Institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.